Abeona Therapeutics receives FDA Fast Track designation for its ABO-202 gene therapy

For the second time since April, Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company co-headquartered in Cleveland and New York, has received Fast Track designation from the U.S. Food and Drug Administration for one of its therapies.

Click here to read the complete article.

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Originally published June 18, 2019.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: